The Lancet Diabetes & Endocrinology
Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study
By Hiddo J.L. Heerspink, Avraham Karasik, Marcus Thuresson, Show 13 more authorsMikhail N. Kosiborod
Cohort study of 65,231 peopleInterventions
Multicentre
- SGLT2 inhibitors
- Canagliflozin
- SLC5A2
- Type 2 diabetes
- 50% eGFR decline or end-stage kidney disease
- Humans
The paper
University Medical Center Groningen; UNSW Sydney
The Lancet Diabetes & Endocrinology, 1 Jan 2020